Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups

Abstract

PurposeThe computer-assisted diagnostic system for bone scintigraphy (BS) BONENAVI is used to evaluate skeletal metastasis. We investigated its diagnostic performance in prostate cancer patients with and without skeletal metastasis and searched for the problems.MethodsAn artificial neural network (ANN) value was calculated in 226 prostate cancer patients (124 with skeletal metastasis and 101 without) using BS. Receiver operating characteristic curve analysis was performed and the sensitivity and specificity determined (cutoff ANN = 0.5). Patient’s situation at the time of diagnosis of skeletal metastasis, computed tomography (CT) type, extent of disease (EOD), and BS uptake grade were analyzed. False-negative and false-positive results were recorded.ResultsBONENAVI showed 82% (102/124) of sensitivity and 83% (84/101) specificity for metastasis detection. There were no significant differences among CT types, although low EOD and faint BS uptake were associated with low ANN values and low sensitivity. Patients showed lower sensitivity during the follow-up period than staging work-up. False-negative lesions were often located in the pelvis or adjacent to it. They comprised not only solitary, faint BS lesions but also overlaying to urinary excretion.ConclusionsBONENAVI with BS has good sensitivity and specificity for detecting prostate cancer’s osseous metastasis. Low EOD and faint BS uptake are associated with low sensitivity but not the CT type. Prostate cancer patients likely to have false-negative results during the follow-up period had a solitary lesion in the pelvis with faint BS uptake or lesions overlaying to urinary excretion.

Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients

“…We have investigated that BONENAVI ® often resulted in false-positive or false-negative in patients with small tumor burden (e.g., EOD = 1 and low activity) [ 24 ]. Others have also reported that BSI was strongly influenced by tumor location, volume, and scan uptake time in a simulation study [ 25 ] and clinical setting [ 26 ].…”

Analysis of orthopedic surgery of patients with metastatic bone tumors and pathological fractures

“… 25 Internal fixation may be performed if the expected survival is >6 weeks, the patient’s general condition is suitable for surgery, mobilization is expected after internal fixation, the structure and quality of the bone both proximal and distal to the focal bone lesion can support the internal fixation, and/or pain persists despite ≥4 weeks of a sufficient dose of radiotherapy. 26 …”

The Application of Artificial Intelligence in Prostate Cancer Management—What Improvements Can Be Expected? A Systematic Review

“…Regarding detection of PCa metastases, Koizumi et al reported the ability of an ANN algorithm, to identify skeletal metastases with an accuracy of 80% on bone scintigraphy. However, regarding the detection of non-skeletal metastasis, the performance of the model decreased to 22%, [39]. After treatment, metastatic lesions stand sclerotic and it can be difficult to identify recurrence.…”